So far, especially in combined use with anti-angiogenetic targeted therapy, VEGF levels have been reported as potential marker in several studies, e.g., for breast cancer [46], in regards of better patients stratification or treatment success. The gene discussed is VEGFA; the disease is breast carcinoma.